Evidence map›Paper›PMID 39504114›Full record

ArticleOrganic & biomolecular chemistry2024

Synthesis of the 5/5-spiroindimicin alkaloids: development of a general synthetic approach and biological investigations.

Ankush Banerjee, Tiffany A Brisco, Sneha Ray, Arani Datta, Xiaoyu Zhang, Zhen Zhang, Alexander A Busse, Hanspeter Niederstrasser, Krissty Sumida, Bruce A Posner and 3 more

Abstract read
In one paragraph

Article in Organic & biomolecular chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ankush BanerjeeDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.ORCID 0000-0003-4779-4904
Tiffany A BriscoDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Sneha RayDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Arani DattaDepartment of Pediatrics, UT Southwestern Medical Center, Dallas, Texas 75390, USA.
Xiaoyu ZhangDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Zhen ZhangDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.ORCID 0000-0001-9866-4523
Alexander A BusseDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Hanspeter NiederstrasserDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Krissty SumidaDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Bruce A PosnerDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Dawn M WetzelDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Margaret A PhillipsDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.
Myles W SmithDepartment of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390, USA. myles.smith@utsouthwestern.edu.ORCID 0000-0002-0231-0059

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
Lead Optimization of DHODH Inhibitors for MalariaR01AI103947 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Margaret A. Phillips · 2013 to 2026
$9.7M
TRYPANSOMIASIS--MOLECULAR APPROACHES TO CHEMOTHERAPYR01AI034432 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI PHILLIPS, MARGARET A. · 1995 to 2024
$4.9M
Targeting a New Therapy for TrypanosomatidsR01AI146349 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI WETZEL, DAWN MARIE · 2019 to 2023
$3.0M
An acoustic droplet ejection liquid dipenser for our UTSW HTS CoreS10OD026758 · OD · UT SOUTHWESTERN MEDICAL CENTER · PI POSNER, BRUCE ARTHUR · 2019 to 2019
$337k
NCI NIH HHS P30 CA142543NIAID NIH HHS R01 AI034432NIAID NIH HHS R01 AI103947NIAID NIH HHS R01 AI146349NIH HHS 1S10OD026758-01NIH HHS S10 OD026758
6 · The paper itself

Abstract

We describe the development of a unified synthetic strategy for the preparation of all known 5/5-spirocyclic spiroindimicin (SPM) alkaloids, namely spiroindimicins B-G. The present synthetic route relies on four fundamental transformations: Grignard-based fragment coupling between halogenated pyrrolemetal and isatin partners, Suzuki coupling to generate a triaryl scaffold encompassing all requisite skeletal atoms of the natural products, Lewis acid-mediated spirocyclization to construct the 5/5-spirocyclic core, and chemoselective lactam reduction. The developed syntheses are step-economic (6-7 steps from commercial materials), scalable, and amenable to analogue synthesis. Preliminary investigations into a catalytic asymmetric spirocyclization towards an enantioselective SPM synthesis are also described. Further studies of the antiparasitic properties of this class have revealed promising activity against

Indexed as

AlkaloidsSpiro CompoundsMolecular StructureTrypanosoma brucei bruceiAlkaloidsSpiro Compounds

Identifiers

PMID39504114
PMCPMC12055039

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.